Breaking News Instant updates and real-time market news.

GILD

Gilead

$75.29

0.96 (1.29%)

10:21
04/13/18
04/13
10:21
04/13/18
10:21

Gilead presents data from proof-of-concept study in NASH patients

Gilead Sciences presented today data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis, combining the apoptosis signal-regulating kinase 1 inhibitor selonsertib with either the Acetyl-CoA carboxylase inhibitor GS-0976 or the selective, non-steroidal Farnesoid X receptor (FXR) agonist GS-9674. The data were presented at The International Liver Congress 2018 in Paris. More than 25 additional Gilead abstracts on NASH and other fibrotic liver diseases are also being presented, including data from predictive modeling studies using noninvasive tests for the diagnosis and monitoring of NASH that aim to reduce the need for liver biopsy. The proof-of-concept study included 70 patients. All patients in the study were diagnosed with NASH and liver fibrosis stages F2 to F3 based on biopsy, or by magnetic resonance elastography and MRI proton density fat fraction. The greatest changes observed after 12 weeks of treatment in the study were decreases in liver fat content, which occurred in regimens containing GS-0976. Improvements in liver biochemistry and/or markers of fibrosis were also observed across both combination arms of the study compared to baseline, the company said. In patients treated with selonsertib plus GS-0976, kinetic labeling revealed the largest reduction in the fractional synthesis rate of lumican, a marker of fibrogenesis. Similar rates of adverse events were observed between patients treated with single-agent and combination therapies. No patient discontinued treatment prematurely. "These encouraging results suggest that combination therapy with selonsertib and either GS-0976 or GS-9674 warrants further exploration in longer-term studies in patients with NASH and F3 and F4 fibrosis," said Stephen Harrison, MD, presenting author and Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford, UK. "Patients with advanced fibrosis due to NASH urgently need effective therapeutic options because they may face more serious health risks, including development of complications of end-stage liver disease, liver cancer and the need for liver transplantation. Combination therapy may be a way forward to achieving greater benefit for this patient population."

  • 13

    Apr

  • 20

    Apr

  • 18

    May

GILD Gilead
$75.29

0.96 (1.29%)

03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
03/07/18
LEHM
03/07/18
NO CHANGE
Target $59
LEHM
Overweight
Crispr Therapeutics price target raised to $59 from $29 at Barclays
Barclays analyst Gena Wang raised her price target for Crispr Therapeutics (CRSP) to $59 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Crispr shares and keeps an Overweight rating on the name.
03/06/18
LEHM
03/06/18
NO CHANGE
Target $95
LEHM
Overweight
Gilead target raised to $95 on favorable doctor survey at Barclays
Barclays analyst Geoff Meacham raised his price target for Gilead Sciences to $95 from $90 after his doctor surgery to assess the outlook for the company's HIV franchise was more favorable than expected. The survey shows stronger than expected support for Biktarvy, Meacham tells investors in a research note. Gilead's HIV franchise will "be the bridge until the next leg of growth from CAR-T and the pipeline kicks in," the analyst tells investors in a research note. He keeps an Overweight rating on Gilead.
02/23/18
FBCO
02/23/18
NO CHANGE
Target $80
FBCO
Neutral
Gilead's near-term launches 'intact' after CCO retirement, says Credit Suisse
Credit Suisse analyst Alethia Young told investors in a research note that she is not concerned about the departure of Gilead Sciences' Chief Commercial Officer Jim Myers after speaking with the company's management. She said that she is "confident" in her estimates around the recent launch for Bictarvy and Yescarta, noting that Myers' departure "has nothing to do" with a performance issue or disagreement, adding that Myers had taken a leave of absence earlier in the year due to family matters. She also noted that the company has had turnover in the CCO role with "limited' disruption. Young has a Neutral rating on Gilead shares.

TODAY'S FREE FLY STORIES

BOOT

Boot Barn

$28.61

1.08 (3.92%)

06:12
10/17/18
10/17
06:12
10/17/18
06:12
Recommendations
Boot Barn analyst commentary  »

Boot Barn recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSCO

Tractor Supply

$88.90

2.32 (2.68%)

06:09
10/17/18
10/17
06:09
10/17/18
06:09
Recommendations
Tractor Supply analyst commentary  »

Tractor Supply price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

TRCH

Torchlight Energy Resources

$0.91

-0.0184 (-1.98%)

06:07
10/17/18
10/17
06:07
10/17/18
06:07
Conference/Events
Torchlight Energy Resources management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

RYTM

Rhythm Pharmaceuticals

$28.09

1.56 (5.88%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Conference/Events
Rhythm Pharmaceuticals management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

TSLA

Tesla

$276.46

16.88 (6.50%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Periodicals
Tesla secures site in Shanghai for new Gigafactory, Reuters reports »

Tesla has signed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Nov

  • 13

    Dec

AKRX

Akorn

$6.71

0.445 (7.11%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Upgrade
Akorn rating change  »

Akorn upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$30.39

0.98 (3.33%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Hot Stocks
Maxar Technologies subsidiary awarded up to $7M NASA contract »

DigitalGlobe, a Maxar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMUC

ImmunoCellular

$0.05

-0.173 (-76.55%)

06:03
10/17/18
10/17
06:03
10/17/18
06:03
Hot Stocks
ImmunoCellular receives notice of noncompliance from NYSE, stock to be delisted »

ImmunoCellular announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSNAY

RSA Insurance

$0.00

(0.00%)

06:03
10/17/18
10/17
06:03
10/17/18
06:03
Conference/Events
RSA Insurance management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MEI

Methode Electronics

$30.08

0.73 (2.49%)

06:03
10/17/18
10/17
06:03
10/17/18
06:03
Conference/Events
Methode Electronics management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNCE

Concert Pharmaceuticals

$15.59

0.64 (4.28%)

06:01
10/17/18
10/17
06:01
10/17/18
06:01
Conference/Events
Concert Pharmaceuticals management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

LYFT

Lyft

$0.00

(0.00%)

, JPM

JPMorgan

$108.65

2.31 (2.17%)

06:00
10/17/18
10/17
06:00
10/17/18
06:00
Periodicals
Lyft picks JPMorgan to lead IPO, which could be valued at over $15B, CNBC says »

Lyft (LYFT) has hired…

LYFT

Lyft

$0.00

(0.00%)

JPM

JPMorgan

$108.65

2.31 (2.17%)

UBER

Uber

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

ALB

Albemarle

$97.15

1.02 (1.06%)

06:00
10/17/18
10/17
06:00
10/17/18
06:00
Conference/Events
Albemarle management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

BMO

Bank of Montreal

$80.19

0.93 (1.17%)

05:59
10/17/18
10/17
05:59
10/17/18
05:59
Conference/Events
Bank of Montreal to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

TWTR

Twitter

$29.86

1.25 (4.37%)

05:57
10/17/18
10/17
05:57
10/17/18
05:57
Periodicals
Twitter banned 1,500 accounts for misleading election-related content, NYT says »

Over the weekend, Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

TSLA

Tesla

$276.46

16.88 (6.50%)

05:57
10/17/18
10/17
05:57
10/17/18
05:57
Hot Stocks
Tesla's Musk vows to fix 'foolish oversight' in service locations »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Nov

  • 13

    Dec

GOOG

Alphabet

$1,120.11

28.11 (2.57%)

, GOOGL

Alphabet Class A

$1,133.71

32.13 (2.92%)

05:52
10/17/18
10/17
05:52
10/17/18
05:52
Hot Stocks
YouTube resolves widespread access issues also impacgint YouTube TV, Music »

YouTube says it has…

GOOG

Alphabet

$1,120.11

28.11 (2.57%)

GOOGL

Alphabet Class A

$1,133.71

32.13 (2.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

SSNLF

Samsung

$0.00

(0.00%)

05:50
10/17/18
10/17
05:50
10/17/18
05:50
Hot Stocks
Samsung to acquire Zhilabs to expand AI-based automation portfolio »

Samsung Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,818.00

57.01 (3.24%)

05:47
10/17/18
10/17
05:47
10/17/18
05:47
Periodicals
Amazon employee on Medium: Employees asked Bezos to kick Palantir off AWS »

An anonymous Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

LOW

Lowe's

$105.97

1.31 (1.25%)

05:41
10/17/18
10/17
05:41
10/17/18
05:41
Downgrade
Lowe's rating change  »

Lowe's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

HD

Home Depot

$193.61

2.51 (1.31%)

05:40
10/17/18
10/17
05:40
10/17/18
05:40
Downgrade
Home Depot rating change  »

Home Depot downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$18.72

0.38 (2.07%)

05:40
10/17/18
10/17
05:40
10/17/18
05:40
Downgrade
U.S. Silica rating change  »

U.S. Silica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CVIA

Covia

$7.58

0.18 (2.43%)

05:39
10/17/18
10/17
05:39
10/17/18
05:39
Downgrade
Covia rating change  »

Covia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SND

Smart Sand

$3.81

-0.07 (-1.80%)

05:39
10/17/18
10/17
05:39
10/17/18
05:39
Downgrade
Smart Sand rating change  »

Smart Sand downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$9.49

-0.16 (-1.66%)

05:38
10/17/18
10/17
05:38
10/17/18
05:38
Downgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.